An observational study in Heart Failure Risk Factors in Healthy Individuals, sponsored by The Cleveland Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Heart Failure by The Cleveland Clinic — 8 open to participants now, 10 under way, none of them phase 3. Heart Failure · The Cleveland Clinic.
Among the 23 studies in Heart Failure by The Cleveland Clinic, this one has the largest enrollment of the 12 observational ones that give a count, is the only one that started in 2010, is one of 12 observational ones, and was the 8th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →8 of the 23 studies in Heart Failure by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 40+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,208 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 50 across the 11 interventional studies, 200 across the 12 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
3 of the studies in Heart Failure by The Cleveland Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03012022The Cleveland ClinicCleveland Heart and Metabolic Prevention Study | 2027-06 |
| NCT06849752The Cleveland ClinicEarly Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF | 2027-06 |
| NCT05650307The Cleveland ClinicCV Imaging of Metabolic Interventions | 2027-09-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Heart Failure by The Cleveland Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to investigate the role of chemical reactions, such as inflammation and oxidation, in the cause of cardiac dysfunction (the heart does not function properly). The investigators are interested in studying the various chemical pathways for cell damage to determine which are the most prevalent and/or most important. The investigators also want to determine whether waste products of oxidative damage or other chemicals can be monitored in the blood or urine and serve as an indication of the existence and severity of overall heart disease activity. The investigators further want to determine whether certain proteins, called enzymes, affect this cell damage, or whether the presence or absence of certain genes which create different forms of these enzymes correlate with the development of heart failure or cardiomyopathy (weakening of the heart muscle or a change in heart muscle structure) or other cardiovascular diseases.
This is a single-center study conducted at the Cleveland Clinic. The target population for this study is very broad and goes beyond any specific cohort or community. Participants will be mainly recruited from the greater Cleveland/Akron area, but any volunteer meeting the inclusion/exclusion criteria is eligible for participation.
The overall goal of the Cleveland Heart And Metabolic Prevention Study (CHAMPS) is to determine the role of nitrative stress in the development and progression of heart failure (HF) and left ventricular systolic dysfunction (LVSD). The investigators have previously developed and performed preliminary clinical validation studies on multiple specific molecular footprints of known pathways of nitric oxide (NO) pathobiology that affect substrate availability for NO production or generation of NO-derived oxidants as a result of nitrative stress. For each these molecular markers and indices, mechanistic links to cardiovascular diseases have been demonstrated. However, these processes may be differentially expressed in different proportions at different stages of LVSD/HF disease progression, and certainly may vary among different individuals. It is the investigators' hypothesis that the interplay of many of these processes contribute to development of subclinical myocardial dysfunction (SMD), and the progression to overt LVSD and HF.
In order to help determine the role of nitrative stress in the development and progression of heart failure and left ventricular systolic dysfunction study participants will receive many non-invasive, research only, procedures as well as a blood draw and urine collection. The procedures performed may include electrocardiogram (ECG), echocardiogram, carotid intima-medial thickness measurements, ankle-brachial index, bioelectrical impedance analysis, pulse wave velocity analysis, spirometry, exhaled nitric oxide analysis, and venous occlusion strain-gauge plethysmography. The specific tests performed on each participant will be at the description of the primary investigator and not all participants will receive all tests. All participants will have blood and urine collections and all participants will be asked to fill out questionnaires pertaining to family history, personal medical history and estimates of functional capacity.
Specific aims include:
Aim 1: To test the hypothesis that levels of specific nitric oxide (NO)-mediated processes are associated with the presence of SMD and LVSD/HF.
Aim 2: To test the hypothesis that levels of specific NO-mediated processes are associated with prospective risks for development of adverse cardiovascular events and overt HF in stable patients without LVSD/HF at baseline.
Healthy volunteers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Volunteers without known cardiomyopathy or heart failure
Correlation between metabolic and/or nitrative stress markers and predefined clinical endpoints
Clinical endpoints include acute myocardial infarction, acute coronary syndrome, congestive heart failure, serious cardiac arrhythmia, peripheral vascular disease, cerebrovascular events and death. Events will be aggregated into a common category (e.g. MACE) for statistical analysis and reporting. These aggregated events data will then be correlated with each biomarker of interest.
Time frame: 10 years
Determination of sub-clinical myocardial dysfunction by echocardiogram
Determination of sub-clinical myocardial dysfunction by echocardiogram
Time frame: 10 years
Correlation between DASI functional capacity and markers of metabolic and nitrative stress
Correlation between functional capacity, as measured by the Duke Activity Status Index (DASI) questionnaire, and markers of metabolic and nitrative stress
Time frame: 10 years
Correlation between SF36 functional capacity and markers of metabolic and nitrative stress
Correlation between functional capacity, as measured by the SF36 version 2 questionnaire, and markers of metabolic and nitrative stress
Time frame: 10 years
Correlation between DASI functional capacity and markers of cardiac dysfunction
Correlation between functional capacity, as measured by DASI questionnaire, and markers of cardiac dysfunction
Time frame: 10 years
Correlation between SF36 functional capacity and markers of cardiac dysfunction
Correlation between functional capacity, as measured by SF36 version 2 questionnaire, and markers of cardiac dysfunction
Time frame: 10 years
Plan to share: No
Started Nov 2010 (actual). Primary completion is estimated for Jun 2027, 199 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 199 months is above that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.